Home' Australian Pharmacist : Australian Pharmacist March 2016 Contents Australian Pharmacist March 2016 I ©Pharmaceutical Society of Australia Ltd.
Make the dream of becoming a doctor a reality, earn
your MD at Oceania University of Medicine.
n Attractive fee structure for our Graduate Entry Program.
n Over 150 students currently enrolled and over 50
graduates in Australia, New Zealand, Samoa and USA.
n Home-based Pre-Clinical Study under top international
medical school scholars, using world leading Pre-Clinical,
24/7 online delivery techniques.
n Clinical Rotations can be performed locally, Interstate or
n Receive personalised attention from an Academic Advisor.
n OUM Graduates are eligible to sit the AMC exam or NZREX.
OCEANIA UNIVERSITY OF MEDICINE
INTERNATIONALLY ACCREDITED For information visit www.oceaniamed.org or 1300 665 343
Applications now open for courses starting in January & July - No age restrictions
BPharm to MD
is allowing me
to realise my
Pharmacist from Cairns
Class of 2017
DDS pharmacist Jack Clark test a customer.
In an effort to help combat potential
chronic illnesses, Discount Drug
Stores (DDS) across the country are
offering health assessments with an
in-store pharmacist to assess early
asymptomatic signs and identify
Between 10 February and 11 March,
pharmacists are assessing individuals in a
one-on-one consultation, and educating
on ways to help close the gap between a
lifestyle age and biological age.
Frontline pharmacists, who are qualified,
skilled and experienced in identifying
and treating minor ailments, are
discussing history and lifestyle habits,
and offering a general health assessment
through proactive screening and basic
health measurements including blood
pressure and weight, height and waist
DDS Pharmaceuticals Manager Stephenie
Shea said recent studies had shown that
one in five Australians were affected by
multiple chronic diseases.
‘Australians are most at risk of high
blood pressure, diabetes, depression and
arthritis,’ she said.
‘Destructive lifestyle habits are at the
forefront of this prevalence and it’s our
goal to help Australians understand the
impact their lifestyle has on their health,
and offer tips and strategies to help
prevent chronic disease.
‘If a 35 year old comes in presenting
with a lifestyle age of a 50 year old,
we believe it’s our duty as healthcare
professionals to educate and help
find solutions to bring their lifestyle
age in line with their biological age.
The assessments offer a convenient
screening tool for all ages, so if it’s been
a while since you had an overall health
assessment, now’s the time for a reality
check,’ she said.
In store health checks are performed by
qualified pharmacists for a nominal fee
and must be booked online.
Australian cancer drug
A promising cancer drug, developed in
Australia by the Cancer Therapeutics
CRC (CTx), has been licensed to US
pharmaceutical company Merck in a
deal worth $730 million.
The drug, which was developed with
support from the UK-based Wellcome
Trust and Cancer Research Technology
(CRT), has potential clinical applications
in both cancer and hemoglobinopathies
(non-cancer blood disorders).
According to Dr Tom Peat from CSIRO,
one of the key research partners in
CTx, the drug is designed to inhibit the
protein PRMT5, which is associated with
a range of cancers, including mantle cell
lymphoma, lung cancer, breast cancer
and colorectal cancer.
‘Patients who have these types of
cancers often have high levels of
this protein, which is unfortunately
also linked to poor survival rates,’ Dr
‘Using our recombinant protein
production facilities, we were able to
produce samples of these proteins,
crystallise them for structure based drug
design and support the consortium’s
pre-commercial investigations and
trials. Access to high quality protein is
absolutely critical in structural biology
approaches to drug discovery, and
CSIRO is pleased to be able to contribute
this key capability.’
The CTx consortium was able to develop
a drug that binds to this protein,
allowing it to target the cancerous cells.
Under the terms of the license, Merck
US will now further develop the drug,
taking it to clinical trials, with a view to
Links Archive Australian Pharmacist February 2016 Australian Pharmacist April 2016 Navigation Previous Page Next Page